NCT02728947View on ClinicalTrials.gov

Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

September 30, 2016

Conditions

Parkinson's Disease

Interventions

DRUG

ROTIGOTINE

1 week at each dose

Trial Locations (3)

30331

Atlanta Center for Medical Research, Atlanta

33009

MD Clinical, Hallandale

90806

CNS Network, Long Beach

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY

NCT02728947 - Pharmacokinetic Profile of Neupro Patch Administrated at 2 mg, 4 mg, 6 mg and 8 mg/Day Weekly in Patients With Early-stage Parkinson's Disease | Biotech Hunter | Biotech Hunter